Logo Image
|Articles|January 2, 2017

BioPharm International

  • BioPharm International-01-01-2017
  • Volume 30
  • Issue 1

Fully Automated Capping Systems

The Thermo Scientific Decapper 500 and 550 series tube capping systems are fully automated capping systems for use in medium- to high-throughput biotech, pharmaceutical, and clinical laboratories doing compound storage, high-throughput screening, biobanking, and genomic storage.

The Thermo Scientific Decapper 500 and 550 series tube capping systems from Thermo Fisher Scientific and Hamilton Storage are fully automated capping systems for use in medium- to high-throughput biotech, pharmaceutical, and clinical laboratories doing compound storage, high-throughput screening, biobanking, and genomic storage. The systems allow users to cap and decap both Thermo Scientific Matrix and Nunc automation tubes without multiple pieces of equipment. The new decapper system features Quick Switch technology that allows users to transition between different tube and rack types. The systems can also cap and decap partial racks of tubes. The Decapper 550 provides additional functionality with its built-in barcode reader.

Thermo Fisher Scientific 

 

Articles in this issue

almost 10 years ago

Monitoring Temperature-Controlled Chambers

almost 10 years ago

Point-of-Use Leak Testing of Single-Use Bag Assemblies

almost 10 years ago

Staffing and Preparation for Audits

almost 10 years ago

The Evolving Role of HTA Bodies Sparks Scrutiny

almost 10 years ago

Packaging’s Flexible, Patient-Centered Future

almost 10 years ago

The Tide Stays High

almost 10 years ago

Drug Quality Key to Innovation and Access

almost 10 years ago

Using Microcalorimetry to Accelerate Drug Development

almost 10 years ago

Global Drug Spending: A Look Ahead

almost 10 years ago

New Year, New Challenges Ahead

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more